The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sub-urothelial durvalumab injection-1 (SUBDUE-1): A novel approach to immunotherapy for bladder cancer.
 
Pravin Viswambaram
No Relationships to Disclose
 
Andrew Moe
No Relationships to Disclose
 
Elizabeth Chien Hern Liow
Travel, Accommodations, Expenses - Pfizer
 
Andrew David Redfern
Honoraria - Eisai; Novartis; Pfizer; Roche
Consulting or Advisory Role - Eisai; Novartis; Pfizer; Roche
Research Funding - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Nicole Swarbrick
Travel, Accommodations, Expenses - AstraZeneca
 
Tom Ferguson
Research Funding - AstraZeneca (Inst); Janssen (Inst); MSD (Inst)
Travel, Accommodations, Expenses - MSD; Roche
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Dickon Hayne
Honoraria - AstraZeneca; Merck Sharp & Dohme
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme
Research Funding - AstraZeneca; Telix Pharmaceuticals